公开(公告)号：US09417247B2

公开(公告)日：2016-08-16

申请号：US14617412

申请日：2015-02-09

Applicant: The Johns Hopkins University

Inventor： Antony Rosen ,  Erika Lynn Darrah ,  Felipe Andrade ,  Jon Tyler Giles

IPC: G01N33/53 ,  G01N33/68 ,  G01N33/564

CPC classification number: G01N33/686 ,  G01N33/564 ,  G01N2333/978 ,  G01N2800/102 ,  G01N2800/12 ,  G01N2800/52

Abstract: In one or more embodiments, the present invention provides a novel biomarker which provides a link between a distinct clinical phenotype and a biochemical effect of an autoantibody on an enzyme implicated in disease pathogenesis. In particular, the present invention provides an isolated or purified human autoantibody to PAD3 protein. Methods of diagnosis of subjects for rheumatoid arthritis (RA) using these antibodies as well as diagnosis of the severity of RA in the subject, and methods for monitoring treatment of a subject with RA are also provided. The biomarkers provided herein are also useful in the diagnosis of connective tissue-interstitial lung disease (CT-ILD) in patients having or suspected of having RA.

公开(公告)号：US20160184420A1

公开(公告)日：2016-06-30

申请号：US15067469

申请日：2016-03-11

Applicant: GlaxoSmithKline Biologicals, S.A.

Inventor： James BROWN ,  Pascal METTENS ,  Dennis MURPHY

IPC: A61K39/04

CPC classification number: A61K39/04 ,  A61K2039/53 ,  A61K2039/55555 ,  A61K2039/55572 ,  A61K2039/55577 ,  C07H21/04 ,  C07K14/35 ,  G01N2333/35 ,  G01N2800/12

Abstract: The present invention is directed to a polypeptide which comprises: (i) an Rv1753c protein sequence; (ii) a variant of an Rv1753c protein sequence; or (iii) an immunogenic fragment of an Rv1753c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.

Abstract translation: 本发明涉及一种多肽，其包含：（i）Rv1753c蛋白序列; （ii）Rv1753c蛋白序列的变体; 或（iii）Rv1753c蛋白序列的免疫原性片段。 在其它方面，本发明涉及用于治疗或预防结核病的相关多核苷酸，融合蛋白和方法。

公开(公告)号：US20160169889A1

公开(公告)日：2016-06-16

申请号：US15047983

申请日：2016-02-19

Applicant: Mochida Pharmaceutical Co., Ltd.

Inventor： Kamon Shirakawa

IPC: G01N33/569 ,  A61K31/665 ,  A61K31/65 ,  A61K31/7008 ,  A61K31/7028 ,  A61K31/43 ,  A61K38/02

CPC classification number: G01N33/56911 ,  A61K31/407 ,  A61K31/43 ,  A61K31/65 ,  A61K31/665 ,  A61K31/7008 ,  A61K31/7028 ,  A61K38/02 ,  A61K38/16 ,  A61K45/00 ,  G01N2333/70596 ,  G01N2800/12 ,  G01N2800/52

Abstract: Provided are a method for detecting respiratory infection associated with bacterial infection, a method for selecting patients with respiratory infection to receive an antibiotic, and a method for determining the timing for ending administration of an antibiotic to a patient with respiratory infection receiving the antibiotic, wherein said methods are characterized in that they are able to appropriately select patients with respiratory infection to whom the antibiotic is to be administered, to adjust the administration period of the antibiotic, and to treat respiratory infection associated with bacterial infection, and in that a measured value of sCD14-ST in urine is used as an indication.

Abstract translation: 提供了一种检测与细菌感染相关的呼吸道感染的方法，选择呼吸道感染患者以接受抗生素的方法，以及用于确定终止对接受抗生素的呼吸道感染的患者施用抗生素的时间的方法，其中 所述方法的特征在于它们能够适当选择要施用抗生素的呼吸道感染患者，以调节抗生素的施用时间，并治疗与细菌感染相关的呼吸道感染，并且测量值 使用尿液中的sCD14-ST作为指标。

公开(公告)号：US09366679B2

公开(公告)日：2016-06-14

申请号：US14390562

申请日：2013-03-28

Applicant: Universitaetsklinikum Freiburg

Inventor： Florian Kollert ,  Anja Saalbach

IPC: G01N33/00 ,  G01N33/68 ,  G01N33/564

CPC classification number: G01N33/6872 ,  G01N33/564 ,  G01N33/6893 ,  G01N2333/70503 ,  G01N2333/70596 ,  G01N2800/10 ,  G01N2800/12 ,  G01N2800/20 ,  G01N2800/321 ,  G01N2800/52

Abstract: A method for the diagnosis and/or therapy control of systemic sclerosis is disclosed wherein soluble CD90 is detected in body fluids. By measuring the concentration of soluble CD90 certain forms of diseases can be differentiated by applying the ex vivo method.

Abstract translation: 公开了一种用于诊断和/或治疗系统性硬化症的方法，其中在体液中检测到可溶性CD90。 通过测量可溶性CD90的浓度，通过应用离体法可以区分某些形式的疾病。

公开(公告)号：US20160022759A1

公开(公告)日：2016-01-28

申请号：US14649455

申请日：2013-12-03

Applicant: David MANN ,  Vascular BioSciences

Inventor： David Mann

IPC: A61K38/08 ,  A61K45/06 ,  C12Q1/34

CPC classification number: A61K38/08 ,  A61K45/06 ,  C12Q1/34 ,  G01N33/6893 ,  G01N2333/926 ,  G01N2800/12 ,  G01N2800/321

Abstract: Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, PAH, inflammation, diabetes, Crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune diseases, asthma, acute lung injury, and adult respiratory distress syndrome. The compositions can also serve as a receptor for disease selective cell penetrating peptides in the cells and extracellular matrix of diseased tissues.

Abstract translation: 公开了用于引发疾病选择性巨噬细胞增多症的组合物和方法。 组合物可以作为疾病活动的标志物，并且作为经历疾病重塑的组织中增强的巨噬细胞增多的触发因素，例如伤口愈合，癌症，PAH，炎症，糖尿病，克罗恩病，溃疡性结肠炎，强直性脊柱炎，子宫内膜疾病，牛皮癣 肠易激综合征，关节炎，纤维化疾病，间质性膀胱炎，自身免疫疾病，哮喘，急性肺损伤和成人呼吸窘迫综合征。 组合物还可以用作疾病选择性细胞穿透肽在患病组织的细胞和细胞外基质中的受体。

公开(公告)号：US20160018411A1

公开(公告)日：2016-01-21

申请号：US14639496

申请日：2015-03-05

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Christoph Ehret ,  Johann Karl ,  Ralf Roeddiger ,  Wolfgang Rollinger ,  Magdalena Swiatek-de Lange

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  A61B5/0205 ,  G01N2333/96411 ,  G01N2333/96433 ,  G01N2800/12 ,  G01N2800/32

Abstract: The present invention relates to a method for differentiating in a patient who suffers from acute shortness of breath (acute dyspnea) between pulmonary disease and cardiac disease. The method is based on measuring the levels of seprase and of a cardiac marker in a sample from said patient. Further envisaged are kits and devices adapted to carry out the method of the present invention.

Abstract translation: 本发明涉及在患有肺疾病与心脏病之间的急性呼吸急促（急性呼吸困难）的患者中进行区分的方法。 该方法基于测量来自所述患者的样品中seprase和心脏标志物的水平。 进一步设想的是适于实施本发明方法的试剂盒和装置。

公开(公告)号：US20150335266A1

公开(公告)日：2015-11-26

申请号：US14720447

申请日：2015-05-22

Applicant: Picomole Instruments Inc.

Inventor： John Cormier

IPC: A61B5/08 ,  G01N21/3504 ,  G01N33/497 ,  G06F19/00 ,  A61B5/097 ,  A61B5/00

CPC classification number: A61B5/082 ,  A61B5/097 ,  A61B5/7271 ,  G01N21/3504 ,  G01N33/497 ,  G01N2033/4975 ,  G01N2800/12 ,  G01N2800/7028

Abstract: A method of determining whether a subject is likely to have a condition includes measuring concentration levels of a plurality of target biomarkers in a sample obtained from the subject; comparing the measured concentration levels to respective reference concentration levels; in the event that the measured concentration level of at least one of the target biomarkers is less than its respective reference concentration level, and the measured concentration level of at least one of the target biomarkers is greater than its respective reference concentration level, providing an indication that the subject is likely to have the condition, and otherwise: providing an indication that the subject is unlikely to have the condition.

Abstract translation: 确定受试者是否可能具有条件的方法包括测量从受试者获得的样品中的多个靶标生物标志物的浓度水平; 将测量的浓度水平与各个参考浓度水平进行比较; 在目标生物标志物中的至少一种目标生物标志物的测量浓度水平小于其各自参考浓度水平的情况下，并且目标生物标志物中至少一种的测量浓度水平大于其各自的参考浓度水平， 该主体可能具有条件，否则：提供主题不太可能具有条件的指示。

公开(公告)号：US20150301021A1

公开(公告)日：2015-10-22

申请号：US14438807

申请日：2013-10-27

Applicant: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD.

Inventor： Hossam Haick ,  Morad Nakhleh

IPC: G01N33/497 ,  G01N27/12 ,  G01N27/26

CPC classification number: G01N33/497 ,  A61B5/082 ,  G01N27/04 ,  G01N27/127 ,  G01N27/22 ,  G01N27/26 ,  G01N2033/4975 ,  G01N2333/35 ,  G01N2800/12 ,  G01N2800/26

Abstract: A sensor technology comprising a single nano-material (gold nanoparticles and/or carbon nanotube) based sensor or a plurality of sensors in conjunction with a pattern recognition algorithm for non-invasive and accurate diagnosis of tuberculosis caused by M. tuberculosis bacteria in a subject. The sensor technology is suitable for population screening of tuberculosis, particularly in resource-poor and developing countries.

Abstract translation: 一种传感器技术，包括基于单个纳米材料（金纳米颗粒和/或碳纳米管）的传感器或多个传感器，结合用于由受试者中结核分枝杆菌引起的非侵入性和准确诊断结核病的模式识别算法 。 传感器技术适用于结核病人群筛查，特别是资源匮乏和发展中国家。

公开(公告)号：US09005982B2

公开(公告)日：2015-04-14

申请号：US13703617

申请日：2011-06-10

Applicant: Mark S. Anderson ,  Anthony K. Shum

Inventor： Mark S. Anderson ,  Anthony K. Shum

IPC: G01N33/00 ,  G01N33/48 ,  G01N33/50 ,  G01N33/68 ,  A01K67/027 ,  G01N33/564

CPC classification number: G01N33/6884 ,  A01K67/027 ,  A01K2227/101 ,  A01K2227/105 ,  A01K2227/106 ,  A01K2267/0325 ,  G01N33/564 ,  G01N2800/12 ,  G01N2800/50

Abstract: The present disclosure is generally related to pulmonary autoantigens. The disclosure provides methods and kits for assessing whether a subject has or is predisposed to interstitial lung disease. Additionally the present disclosure provides methods of treatment and animal models of interstitial lung disease.

Abstract translation: 本公开一般涉及肺自身抗原。 本公开提供了用于评估受试者是否患有间质性肺病的方法和试剂盒。 此外，本公开提供了间质性肺疾病的治疗方法和动物模型。

公开(公告)号：US20140256614A1

公开(公告)日：2014-09-11

申请号：US14239059

申请日：2012-08-16

Applicant: Usamah S. Kayyali

Inventor： Usamah S. Kayyali

IPC: C07K7/08 ,  C07K7/06

CPC classification number: C07K7/08 ,  C07K7/06 ,  C07K16/18 ,  C07K2317/40 ,  C07K2319/10 ,  C07K2319/70 ,  C12N9/12 ,  C12Q1/485 ,  G01N33/5088 ,  G01N2800/12

Abstract: Compositions and methods for activating MK2, augmenting permeability barriers, such as epithelial and/or endothelial barriers, and treating diseases, conditions, disorders, and/or injuries associated therewith, such as pulmonary edema and other lung diseases and injuries are provided herein.

Abstract translation: 本文提供了激活MK2的组合物和方法，增加渗透性屏障，例如上皮和/或内皮屏障，以及治疗与其相关的疾病，病症，和/或损伤，例如肺水肿和其它肺部疾病和损伤。